|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.400 USD | 0.00% |
|
0.00% | -40.17% |
| 05-13 | Procaps Group S.A. Announces Board Changes, Effective May 8, 2025 | CI |
| 02-03 | Top Midday Decliners | MT |
| Capitalization | 459M 393M 366M 339M 628M 39.37B 700M 4.38B 1.67B 18.4B 1.72B 1.69B 67.24B | P/E ratio 2021 |
-9.47x | P/E ratio 2022 | 12.5x |
|---|---|---|---|---|---|
| Enterprise value | 702M 601M 560M 518M 961M 60.21B 1.07B 6.69B 2.56B 28.13B 2.63B 2.58B 103B | EV / Sales 2021 |
3.14x | EV / Sales 2022 | 2.04x |
| Free-Float |
16.97% | Yield 2021 * |
-
| Yield 2022 | - |
More valuation ratios
* Estimated data
More news
More press releases
More news
| 1 month | +25.00% | ||
| 3 months | -4.76% | ||
| 6 months | -16.67% | ||
| Current year | -40.17% |
| 1 month | 0.01 |  | 1.45 |
| Current year | 0.01 | | 2.38 |
| 1 year | 0.01 | | 3.78 |
| 3 years | 0.01 | | 9.41 |
| 5 years | 0.01 | | 11.98 |
| 10 years | 0 | | 11.98 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 51 | 28/01/2025 | |
Melissa Angelini
CEO | Chief Executive Officer | - | 28/01/2025 |
| Chief Tech/Sci/R&D Officer | 61 | 31/12/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 60 | 18/01/2023 | |
| Chairman | 67 | 18/12/2024 | |
| Director/Board Member | - | 18/12/2024 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 0% | 89 M€ | +0.71% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| 0.00% | 0.00% | -44.22% | -84.05% | 158M | ||
| +0.47% | +1.46% | -15.21% | +139.25% | 710B | ||
| +0.90% | +1.37% | +7.24% | -11.55% | 379B | ||
| +2.30% | +2.23% | +16.04% | +27.58% | 344B | ||
| -0.81% | +3.14% | -53.73% | +11.38% | 317B | ||
| -1.43% | +0.66% | +4.14% | -20.57% | 265B | ||
| -1.25% | +1.26% | -0.28% | +18.10% | 244B | ||
| -0.99% | +3.10% | -12.90% | -5.68% | 223B | ||
| +0.37% | +1.98% | -33.34% | -9.44% | 211B | ||
| +1.30% | +0.71% | -6.62% | +20.88% | 162B | ||
| Average | -0.14% | +1.24% | -13.89% | +8.59% | 285.47B | |
| Weighted average by Cap. | -0.07% | +1.10% | -10.34% | +37.35% |
| 2021 | 2022 | |
|---|---|---|
| Net sales | 410M 351M 327M 302M 561M 35.13B 624M 3.91B 1.49B 16.42B 1.54B 1.51B 60B | 410M 351M 327M 302M 561M 35.15B 625M 3.91B 1.49B 16.42B 1.54B 1.51B 60.03B |
| Net income | -101M -86.3M -80.41M -74.36M -138M -8.65B -154M -961M -367M -4.04B -378M -370M -14.77B | 42.54M 36.4M 33.92M 31.36M 58.22M 3.65B 64.81M 406M 155M 1.7B 160M 156M 6.23B |
| Net Debt | 188M 161M 150M 139M 258M 16.15B 287M 1.8B 686M 7.55B 706M 692M 27.58B | 243M 208M 194M 179M 333M 20.84B 370M 2.32B 885M 9.74B 911M 893M 35.58B |
More financial data
* Estimated data
Employees
5,500
Sector
Pharmaceuticals
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- PROCF Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition